Drug intelligence / Profile preview

OBP-004

Development stage: Preclinical
Lead developer: OncoBone Ventures
Modality: Small Molecules
Administration: Oral

Overview

**OBP-004** is a highly potent and selective small-molecule dual inhibitor of cyclin-dependent kinase 9 (CDK9) and CDK13 developed by OncoBone Therapeutics. It demonstrates strong preclinical efficacy in reducing metastatic tumor burden, particularly bone metastases from triple-negative breast cancer (TNBC) and castration-resistant prostate cancer (CRPC), as well as brain, lung, and lymph node metastases in vivo models. OBP-004 also decreases cancer-induced bone loss and bone pain, addressing key unmet needs in bone metastatic disease.[1][2][4][5][8][10][13]

Targets

CDK13CDK9 (Cyclin-dependent kinase 9)

Beyond the preview

Go deeper on OBP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBP-004.

Explore the full profile